Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens

키워드

참고문헌 (96)

1. Akova M, "Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria", Clin Microbiol Infect, 18, pp.439~448 (2012)
2. Queenan AM, "Carbapenemases: the versatile β-lactamases", Clin Microbiol Rev, 20, pp.440~ (2007)
3. Schwaber MJ, "Carbapenem-resistant Enterobacteriaceae:a potential threat", JAMA, 300, pp.2911~2913 (2008)
4. Bratu S, "Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection", Antimicrob Agents Chemother, 49, pp.3018~3020 (2005)
5. Kanj SS, "Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa", Mayo Clin Proc, 86, pp.250~259 (2011)
6. Peleg AY, "Acinetobacter baumannii:emergence of a successful pathogen", Clin Microbiol Rev, 21, pp.538~582 (2008)
7. Lemos EV, "Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis", Clin Microbiol Infect, 20, pp.416~423 (2014)
8. Queenan AM, "Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from CAPITAL Surveillance 2010", Diagn Microbiol Infect Dis, 73, pp.267~270 (2012)
9. Garnacho-Montero J, "Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP", Clin Infect Dis, 36, pp.1111~1118 (2003)
10. Oliveira MS, "Ampicillin", sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp, 2008, pp.61, 1369~1375
11. Garonzik SM, "Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients", Antimicrob Agents Chemother, 55, pp.3284~3294 (2011)
12. Kuo SC, "Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: a matched case-control study", Clin Microbiol Infect, 18, pp.870~876 (2012)
13. Rattanaumpawan P, "Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria", J Antimicrob Chemother, 65, pp.2645~2649 (2010)
14. Swenson JM, "Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods", J Clin Microbiol, 42, pp.5102~5108 (2004)
15. Reddy T, "Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system", Antimicrob Agents Chemother, 54, pp.2235~2238 (2010)
16. Betrosian AP, "Efficacy and safety of high-dose ampicillin", sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, 2008, pp.56, 432~436
17. Muralidharan G, "Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects", Antimicrob Agents Chemother, 49, pp.220~229 (2005)
18. Kim NH, "Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia:susceptibility and clinical outcome", Scand J Infect Dis, 45, pp.315~319 (2013)
19. Lee YT, "Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections", Eur J Clin Microbiol Infect Dis, 32, pp.1211~1220 (2013)
20. Ramirez J, "Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia", Antimicrob Agents Chemother, 57, pp.1756~1762 (2013)
21. Denys GA, "Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)", Ann Clin Microbiol Antimicrob, 12, pp.24~ (2013)
22. Griffith ME, "Minocycline therapy for traumatic wound infections caused by the multidrug-resistant Acinetobacter baumannii-Acinetobacter calcoaceticus complex", Infect Dis Clin Pract, 16, pp.16~19 (2008)
23. Wood GC, "Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia", Intensive Care Med, 29, pp.2072~2076 (2003)
24. Aydemir H, "Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia", Epidemiol Infect, 141, pp.1214~1222 (2013)
25. Durante-Mangoni E, "Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial", Clin Infect Dis, 57, pp.349~358 (2013)
26. Santimaleeworagun W, "In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases", Southeast Asian J Trop Med Public Health, 42, pp.890~900 (2011)
27. Sirijatuphat R, "Colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections : A preliminary study", Antimicrob Agents Chemother, 58, pp.5598~5601 (2014)
28. Batirel A, "Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections", Eur J Clin Microbiol Infect Dis, 33, pp.1311~1322 (2014)
29. Shields RK, "Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients", PLoS One, 7, pp.e52349~ (2012)
30. Sutcliffe JA, "Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens", Antimicrob Agents Chemother, 57, pp.5548~5558 (2013)
31. Solomkin JS, "Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections", Antimicrob Agents Chemother, 58, pp.1847~1854 (2014)
32. Morrow BJ, "Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program", Diagn Microbiol Infect Dis, 75, pp.412~416 (2013)
33. Linden PK, "Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa", Clin Infect Dis, 37, pp.e154~e160 (2003)
34. Falagas ME, "Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients", Int J Antimicrob Agents, 35, pp.194~199 (2010)
35. Hachem RY, "Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients", Antimicrob Agents Chemother, 51, pp.1905~1911 (2007)
36. Kwa AL, "Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa", Clin Infect Dis, 41, pp.754~757 (2005)
37. Lu Q, "Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii", Anesthesiology, 117, pp.1335~1347 (2012)
38. Neuner EA, "Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms", Antimicrob Agents Chemother, 56, pp.5744~5748 (2012)
39. Dinh A, "Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria", Scand J Infect Dis, 44, pp.182~189 (2012)
40. Pontikis K, "Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria", Int J Antimicrob Agents, 43, pp.52~59 (2014)
41. Apisarnthanarak A, "Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin", Int J Antimicrob Agents, 39, pp.271~272 (2012)
42. Takeda S, "In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa", Antimicrob Agents Chemother, 51, pp.826~830 (2007)
43. Mushtaq S, "In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters", J Antimicrob Chemother, 65, pp.2376~2381 (2010)
44. Sievert DM, "Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010", Infect Control Hosp Epidemiol, 34, pp.1~14 (2013)
45. Bratu S, "Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents", J Antimicrob Chemother, 56, pp.128~132 (2005)
46. Castanheira M, "Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallo-β-lactamase-producing Enterobacteriaceae:report from the SENTRY Antimicrobial Surveillance Program", Antimicrob Agents Chemother, 52, pp.570~573 (2008)
47. Satlin MJ, "Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies", Leuk Lymphoma, 54, pp.799~806 (2013)
48. Pena I, "Carbapenemase-producing Enterobacteriaceae in a tertiary hospital in Madrid, Spain: high percentage of colistin resistance among VIM-1-producing Klebsiella pneumoniae ST11 isolates", Int J Antimicrob Agents, 43, pp.460~464 (2014)
49. Poulakou G, "Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens", J Infect, 58, pp.273~284 (2009)
50. Kelesidis T, "Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae:a systematic review of the evidence from microbiological and clinical studies", J Antimicrob Chemother, 62, pp.895~904 (2008)
51. Cobo J, "Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 β-lactamase-producing Klebsiella pneumoniae epidemic clone", Diagn Microbiol Infect Dis, 60, pp.319~322 (2008)
52. Nordmann P, "The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria", Lancet Infect Dis, 9, pp.228~236 (2009)
53. Bogdanovich T, "Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258", Clin Infect Dis, 53, pp.373~376 (2011)
54. Arnold RS, "Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria", South Med J, 104, pp.40~45 (2011)
55. Souli M, "Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek University Hospital", Clin Infect Dis, 46, pp.847~854 (2008)
56. Souli M, "An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes", Clin Infect Dis, 50, pp.364~373 (2010)
57. Daikos GL, "Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections", Antimicrob Agents Chemother, 53, pp.1868~1873 (2009)
58. Kontopidou F, "Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options", Clin Microbiol Infect, 20, pp.O117~O123 (2014)
59. Hirsch EB, "Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection", J Antimicrob Chemother, 65, pp.1119~1125 (2010)
60. Daikos GL, "Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?", Clin Microbiol Infect, 17, pp.1135~1141 (2011)
61. Clancy CJ, "Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients", Am J Transplant, 13, pp.2619~2633 (2013)
62. Endimiani A, "In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and", or colistin, 2010, pp.54, 526~529
63. Michalopoulos A, "Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients:a prospective evaluation", Clin Microbiol Infect, 16, pp.184~186 (2010)
64. Karageorgopoulos DE, "Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases", J Antimicrob Chemother, 67, pp.2777~2779 (2012)
65. Livermore DM, "Temocillin revived", J Antimicrob Chemother, 63, pp.243~245 (2009)
66. Adams-Haduch JM, "Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli", Antimicrob Agents Chemother, 53, pp.2700~2701 (2009)
67. Bulik CC, "In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae", Antimicrob Agents Chemother, 54, pp.4112~4115 (2010)
68. Ho VP, "Use of meropenem by continuous infusion to treat a patient with a blaKPC-2-positive Klebsiella pneumoniae blood stream infection", Surg Infect (Larchmt), 12, pp.325~327 (2011)
69. Tzouvelekis LS, "Treating infections caused by carbapenemase-producing Enterobacteriaceae", Clin Microbiol Infect (2014)
70. Qureshi ZA, "Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens", Antimicrob Agents Chemother, 56, pp.2108~2113 (2012)
71. Zarkotou O, "Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment", Clin Microbiol Infect, 17, pp.1798~1803 (2011)
72. Tumbarello M, "Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae:importance of combination therapy", Clin Infect Dis, 55, pp.943~950 (2012)
73. Daikos GL, "Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems", Antimicrob Agents Chemother, 58, pp.2322~2328 (2014)
74. Lagacé-Wiens P, "Ceftazidime-avibactam:an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections", Core Evid, 9, pp.13~25 (2014)
75. Ehmann DE, "Kinetics of avibactam inhibition against Class A, C, and D β-lactamases", J Biol Chem, 288, pp.27960~27971 (2013)
76. Mushtaq S, "Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae", J Antimicrob Chemother, 65, pp.1428~1432 (2010)
77. Stachyra T, "In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases", J Antimicrob Chemother, 64, pp.326~329 (2009)
78. Endimiani A, "ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates", Antimicrob Agents Chemother, 53, pp.4504~4507 (2009)
79. Nordmann P, "Emerging carbapenemases in Gram-negative aerobes", Clin Microbiol Infect, 8, pp.321~331 (2002)
80. Kim YA, "Features of infections due to Klebsiella pneumoniae carbapenemase-producing Escherichia coli: emergence of sequence type 131", Clin Infect Dis, 55, pp.224~231 (2012)
81. Landman D, "Susceptibility profiles, molecular epidemiology, and detection of KPC-producing Escherichia coli isolates from the New York City vicinity", J Clin Microbiol, 48, pp.4604~4607 (2010)
82. O’Hara JA, "Molecular epidemiology of KPC-producing Escherichia coli: Occurrence of ST131-fimH30 subclone harboring pKpQIL-like IncFIIk plasmid", Antimicrob Agents Chemother, 58, pp.4234~4237 (2014)
83. Zhanel GG, "Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model", J Antimicrob Chemother, 69, pp.2448~2452 (2014)
84. Kaase M, "Fosfomycin susceptibility in carbapenem-resistant Enterobacteriaceae from Germany", J Clin Microbiol, 52, pp.1893~1897 (2014)
85. Novak A, "Monoclonal outbreak of VIM-1-carbapenemase-producing Enterobacter cloacae in intensive care unit, University Hospital Centre Split, Croatia", Microb Drug Resist (2014)
86. Lee Y, "Molecular Mechanisms of Carbapenem Resistance in Enterobacter cloacae Clinical Isolates from Korea and Clinical Outcome", ANNALS OF CLINICAL AND LABORATORY SCIENCE, 42(3), pp.281~286 (2012), ASSOC CLINICAL SCIENTISTS
87. Ahn C, "Microbiological features of KPC-producing Enterobacter isolates identified in a U.S. hospital system", Diagn Microbiol Infect Dis, 80, pp.154~158 (2014)
88. Nicodemo AC, "Antimicrobial therapy for Stenotrophomonas maltophilia infections", Eur J Clin Microbiol Infect Dis, 26, pp.229~237 (2007)
89. Lai CH, "Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia", J Microbiol Immunol Infect, 37, pp.350~358 (2004)
90. Senol E, "Attributable mortality of Stenotrophomonas maltophilia bacteremia", Clin Infect Dis, 34, pp.1653~1656 (2002)
91. Nseir S, "Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome", Crit Care, 10, pp.R143~ (2006)
92. Brooke JS, "Stenotrophomonas maltophilia: an emerging global opportunistic pathogen", Clin Microbiol Rev, 25, pp.2~41 (2012)
93. Wang YL, "Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections", Antimicrob Agents Chemother, 58, pp.176~182 (2014)
94. Cho SY, "Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?", Antimicrob Agents Chemother, 58, pp.581~583 (2014)
95. Lakatos B, "Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia", Infection, 42, pp.553~558 (2014)
96. Tekçe YT, "Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections", J Chemother, 24, pp.150~154 (2012)

관련 논문AI추천